These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 27075383

  • 1. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy.
    Hlavaty T, Krajcovicova A, Letkovsky J, Sturdik I, Koller T, Toth J, Huorka M.
    Bratisl Lek Listy; 2016; 117(4):205-11. PubMed ID: 27075383
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

  • 4. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 5. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP.
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.
    Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T.
    Scand J Gastroenterol; 2017 Mar; 52(3):284-290. PubMed ID: 27806638
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A.
    World J Gastroenterol; 2015 Mar 21; 21(11):3282-90. PubMed ID: 25805935
    [Abstract] [Full Text] [Related]

  • 11. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Gisbert JP, Marín AC, Chaparro M.
    Aliment Pharmacol Ther; 2015 Aug 21; 42(4):391-405. PubMed ID: 26075832
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B, Laharie D.
    Aliment Pharmacol Ther; 2014 Aug 21; 40(4):338-53. PubMed ID: 24957164
    [Abstract] [Full Text] [Related]

  • 14. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE.
    J Clin Gastroenterol; 2016 Feb 21; 50(2):147-51. PubMed ID: 25811118
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study.
    Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE.
    J Clin Gastroenterol; 2018 Mar 21; 52(3):229-234. PubMed ID: 27984399
    [Abstract] [Full Text] [Related]

  • 16. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan 21; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 17. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Lee JM, Kim YJ, Lee KM, Yoon H, Lee BI, Kim DB, Kang D.
    Scand J Gastroenterol; 2018 Jan 21; 53(10-11):1280-1285. PubMed ID: 30351977
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G.
    Aliment Pharmacol Ther; 2019 Jan 21; 49(2):147-154. PubMed ID: 30589970
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.